Doximity price target lowered to $52 from $58 at Truist

Truist analyst Jailendra Singh lowered the firm’s price target on Doximity (DOCS) to $52 from $58 and keeps a Hold rating on the shares. The company posted a mixed print with Q4 results ahead of consensus expectations, but FY26 guidance coming in below consensus, with the management attributing the prudent guidance approach to macro uncertainty and tough Y/Y comps, the analyst tells investors in a research note. Doximity has not yet seen the impact from recent macro uncertainty, though the management expects the pharma HCP digital market to grow at the lower end of 5%-7% market growth rate, the firm added.